Top Back to top

Data Request: Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Richter’s Syndrome

Chronic Malignancies Working Party (CMWP)

Despite the advent of effective targeted therapies, including both BTK and BCR inhibitors, in Chronic Lymphocytic Leukemia (CLL), disease transformation towards Richter’s Syndrome (RS), usually of dismal prognosis, remains a major concern.

The Chronic Malignancies Working Party (CMWP) is looking for transplant centers who treated patients with Richter’s Syndrome (RS) with either an autologous or allogeneic hematopoietic stem cell transplantation (HSCT) between 2008 and 2018. 

While either auto- or allo-HSCT have been retained as the best options as consolidation therapy for eligible patients, updated data are needed for determining their respective interest.

The aim of this retrospective study is to describe the outcomes of patients with RS and treated with either auto- or allo-HSCT.

A data request for this retrospective study was sent out at January 8th this year. If you have eligible patients for this study and did not receive the study invitation, please contact us at Your participation will be highly appreciated.